Mythic: Enhancing ADC payload delivery using pH engineering

Mythic aims to make antibody-drug conjugates that are safer and more effectively internalized by the cells they target by using pH engineering of the antibody, with the goal of treating patients with low expression of the target.

Traditional ADCs are internalized as an intact complex of the ADC bound to its target, and the complex is either trafficked to lysosomes where both the target and ADC are destroyed after the payload is released, or recycled back to the cell surface where the target is preserved, but the antibody may remain bound. In both cases, expression of the free receptor on the cancer cell surface drops...